Skip to main content
Erschienen in: World Journal of Urology 8/2016

05.02.2016 | Topic Paper

Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study

verfasst von: Saeed Dabestani, Andreas Thorstenson, Per Lindblad, Ulrika Harmenberg, Börje Ljungberg, Sven Lundstam

Erschienen in: World Journal of Urology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To present the occurrence of metastases and local recurrences in primary non-metastatic patients with renal cell carcinoma (RCC) in a contemporary Swedish population-based cohort.

Methods

Between 2005 and 2009, a total of 4527 patients were included in the prospective National Swedish Kidney Cancer Register accounting for nearly all RCC patients in Sweden. Among M0 patients, 472 (13 %) had no follow-up data registered within 5-year follow-up time and were excluded from the analysis.

Results

In total, 939 (21 %) had distant metastases at presentation with a decrease from 23 to 18 % during the inclusion period. Of 3107 patients with follow-up data and with M0 disease, 623 (20 %) were diagnosed with a tumor recurrence during 5-year follow-up. Mean time to recurrence was 24 months (SD ± 20 months). Among these, 570 patients (92 %) were at primary diagnosis treated with radical nephrectomy, 23 patients (3.7 %) with partial nephrectomy and 12 patients (1.9 %) with minimally invasive treatments. The most frequent sites of metastases were lung (54 %), lymph nodes (22 %) and bone (20 %). The treatment of recurrence was in 50 % systemic treatments, while metastasectomy was performed in 17 % of the patients, out of which 68 % were with a curative intention.

Conclusions

In this population-based study, 21 % of the patients had metastatic disease at presentation, with a decreasing trend over the study period. During 5-year follow-up, 20 % of the primary non-metastatic patients had recurrent disease. Of the patients with recurrence, half were given systemic oncological treatment and 17 % underwent metastasectomy.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:10.1002/ijc.29210 CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:10.​1002/​ijc.​29210 CrossRefPubMed
5.
Zurück zum Zitat Gandaglia G, Ravi P, Abdollah F, Abd-El-Barr AE, Becker A, Popa I, Briganti A, Karakiewicz PI, Trinh QD, Jewett MA, Sun M (2014) Contemporary incidence and mortality rates of kidney cancer in the United States. Can Urol Assoc J 8(7–8):247–252. doi:10.5489/cuaj.1760 PubMedPubMedCentral Gandaglia G, Ravi P, Abdollah F, Abd-El-Barr AE, Becker A, Popa I, Briganti A, Karakiewicz PI, Trinh QD, Jewett MA, Sun M (2014) Contemporary incidence and mortality rates of kidney cancer in the United States. Can Urol Assoc J 8(7–8):247–252. doi:10.​5489/​cuaj.​1760 PubMedPubMedCentral
6.
Zurück zum Zitat Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924. doi:10.1016/j.eururo.2015.01.005 CrossRefPubMed Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924. doi:10.​1016/​j.​eururo.​2015.​01.​005 CrossRefPubMed
7.
Zurück zum Zitat Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, Shariat SF, Montorsi F, Patard JJ, Perrotte P, Karakiewicz PI (2011) Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 59(1):135–141. doi:10.1016/j.eururo.2010.10.029 CrossRefPubMed Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, Shariat SF, Montorsi F, Patard JJ, Perrotte P, Karakiewicz PI (2011) Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 59(1):135–141. doi:10.​1016/​j.​eururo.​2010.​10.​029 CrossRefPubMed
8.
Zurück zum Zitat Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980. doi:10.1093/annonc/mdr362 CrossRefPubMed Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980. doi:10.​1093/​annonc/​mdr362 CrossRefPubMed
10.
Zurück zum Zitat Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TB, Canfield SE, Staehler M, Powles T, Ljungberg B, Bex A (2014) Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 15(12):e549–e561. doi:10.1016/S1470-2045(14)70235-9 CrossRefPubMed Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TB, Canfield SE, Staehler M, Powles T, Ljungberg B, Bex A (2014) Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 15(12):e549–e561. doi:10.​1016/​S1470-2045(14)70235-9 CrossRefPubMed
14.
Zurück zum Zitat Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J, Lundstam S (2014) Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol 48(3):231–238. doi:10.3109/21681805.2013.864698 CrossRefPubMed Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J, Lundstam S (2014) Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol 48(3):231–238. doi:10.​3109/​21681805.​2013.​864698 CrossRefPubMed
15.
Zurück zum Zitat Thorstenson A, Harmenberg U, Lindblad P, Ljungberg B, Lundstam S, Swedish Kidney Cancer Quality Register G (2015) Impact of quality indicators on adherence to National and European guidelines for renal cell carcinoma. Scand J Urol. doi:10.3109/21681805.2015.1059882 PubMed Thorstenson A, Harmenberg U, Lindblad P, Ljungberg B, Lundstam S, Swedish Kidney Cancer Quality Register G (2015) Impact of quality indicators on adherence to National and European guidelines for renal cell carcinoma. Scand J Urol. doi:10.​3109/​21681805.​2015.​1059882 PubMed
16.
Zurück zum Zitat Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York
17.
Zurück zum Zitat Elbe JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2004) Pathology and genetics of tumours of the urinary system and male genital organs (IARC WHO classification of tumours). IARC Press, Lyon Elbe JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2004) Pathology and genetics of tumours of the urinary system and male genital organs (IARC WHO classification of tumours). IARC Press, Lyon
18.
Zurück zum Zitat Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7):655–663CrossRefPubMed Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7):655–663CrossRefPubMed
20.
Zurück zum Zitat Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97(7):1663–1671. doi:10.1002/cncr.11234 CrossRefPubMed Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97(7):1663–1671. doi:10.​1002/​cncr.​11234 CrossRefPubMed
21.
Zurück zum Zitat Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P (2006) Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 24(19):3101–3106. doi:10.1200/JCO.2005.04.8280 CrossRefPubMed Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P (2006) Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 24(19):3101–3106. doi:10.​1200/​JCO.​2005.​04.​8280 CrossRefPubMed
22.
Zurück zum Zitat O’Malley RL, Hayn MH, Brewer KA, Underwood W 3rd, Hellenthal NJ, Kim HL, Sorokin I, Schwaab T (2015) Cancer control of partial nephrectomy for high-risk localized renal cell carcinoma: population-based and single-institutional analysis. World J Urol. doi:10.1007/s00345-015-1538-z PubMed O’Malley RL, Hayn MH, Brewer KA, Underwood W 3rd, Hellenthal NJ, Kim HL, Sorokin I, Schwaab T (2015) Cancer control of partial nephrectomy for high-risk localized renal cell carcinoma: population-based and single-institutional analysis. World J Urol. doi:10.​1007/​s00345-015-1538-z PubMed
23.
Zurück zum Zitat Andersson M, Hashimi F, Lyrdal D, Lundstam S, Hellstrom M (2015) Improved outcome with combined US/CT guidance as compared to US guidance in percutaneous radiofrequency ablation of small renal masses. Acta Radiol 56(12):1519–1526. doi:10.1177/0284185114558974 CrossRefPubMed Andersson M, Hashimi F, Lyrdal D, Lundstam S, Hellstrom M (2015) Improved outcome with combined US/CT guidance as compared to US guidance in percutaneous radiofrequency ablation of small renal masses. Acta Radiol 56(12):1519–1526. doi:10.​1177/​0284185114558974​ CrossRefPubMed
24.
Zurück zum Zitat Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13):2873–2882. doi:10.1002/cncr.25836 CrossRefPubMed Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13):2873–2882. doi:10.​1002/​cncr.​25836 CrossRefPubMed
26.
Zurück zum Zitat Chen DY, Uzzo RG, Viterbo R (2014) Thinking beyond surgery in the management of renal cell carcinoma: the risk to die from renal cell carcinoma and competing risks of death. World J Urol 32(3):607–613. doi:10.1007/s00345-014-1285-6 CrossRefPubMed Chen DY, Uzzo RG, Viterbo R (2014) Thinking beyond surgery in the management of renal cell carcinoma: the risk to die from renal cell carcinoma and competing risks of death. World J Urol 32(3):607–613. doi:10.​1007/​s00345-014-1285-6 CrossRefPubMed
Metadaten
Titel
Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study
verfasst von
Saeed Dabestani
Andreas Thorstenson
Per Lindblad
Ulrika Harmenberg
Börje Ljungberg
Sven Lundstam
Publikationsdatum
05.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 8/2016
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-016-1773-y

Weitere Artikel der Ausgabe 8/2016

World Journal of Urology 8/2016 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.